Free Trial
→ Get Ready for Elon Musk’s BIGGEST Comeback Yet (From Brownstone Research) (Ad)
NASDAQ:CRVO

CervoMed 8/8/2023 Earnings Report

CervoMed logo
$7.60 +0.13 (+1.74%)
As of 03:24 PM Eastern
ProfileEarnings HistoryForecast

CervoMed EPS Results

Actual EPS
-$1.56
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CervoMed Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CervoMed Announcement Details

Quarter
Date
8/8/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CervoMed's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

CervoMed Earnings Headlines

CervoMed's (CRVO) "Buy" Rating Reiterated at D. Boral Capital
June 12 at 3:26 AM | americanbankingnews.com
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
June 10 at 10:48 AM | tmcnet.com
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
June 12, 2025 | Brownstone Research (Ad)
Comparing CervoMed (CRVO) & Its Competitors
June 10 at 2:15 AM | americanbankingnews.com
Financial Review: CervoMed (CRVO) vs. Its Rivals
June 3, 2025 | americanbankingnews.com
CervoMed (CRVO) & The Competition Head to Head Contrast
June 2, 2025 | americanbankingnews.com
See More CervoMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email.

About CervoMed

CervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

View CervoMed Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles